Navigation Links
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Date:7/29/2013

BOULDER, Colo., July 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the fourth quarter and full year of fiscal 2013 on Wednesday, August 7, 2013 and hold a conference call to discuss those results on Thursday, August 8, 2013.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Conference Call InformationDate:Thursday, August 8, 2013Time:9:00 a.m. eastern timeToll-Free:(800) 447-0521Toll:(847) 413-3238Pass Code:35320184Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
3. Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
4. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
5. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
6. Array BioPharma Announces Proposed Public Offering of Convertible Debt
7. Two Array Invented MEK Inhibitors Showcased At ASCO
8. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
9. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
10. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
11. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):